Visit US Healthcare Professionals Site

Get Answers to Your Questions About SUSVIMO®

SUSVIMO is the first and only device for people with wet AMD that continuously deliverers treatment.*

  • SUSVIMO is an implant placed in your eye during a one-time surgical procedure.†
  • Over the next 6 months, SUSVIMO slowly releases medicine into your eye, continuously delivering treatment.‡
  • The medicine inside the implant is called ranibizumab. It has been trusted by Retina Specialists for years to treat wet AMD.

SUSVIMO is for adults with neovascular (wet) age-related macular degeneration who have been treated with at least 2 injections of a vascular endothelial growth factor inhibitor in the gel-like (vitreous) part of the eye.

Talk to your Retina Specialist to determine if you are eligible for SUSVIMO.

Yes. Treatment with SUSVIMO requires an implant to be placed in the affected eye during a one-time surgical procedure. After that, your Retina Specialist may schedule follow-up visits to make sure your eye has healed.

After receiving your SUSVIMO implant, your eye will need time to heal. Once it heals, you shouldn’t notice the implant or experience any pain or discomfort.

The SUSVIMO implant is located underneath the eyelid and not visible to others.

The most serious side effects of SUSVIMO are:

  • Endophthalmitis: This is an infection of the tissues or fluids inside the eyeball. You may experience eye pain with progressive vision loss, sensitivity to light, or redness in the white of the eye
  • Conjunctival erosion: This occurs when the implant is exposed because of a problem with the layer of the eye that covers the white part of the eye (conjunctiva). You may experience the feeling that something is in your eye or eye discharge/watering
  • Conjunctival retraction: If the stitches in your eye open, this can create a gap in the layer that covers the white part of the eye (conjunctiva). A conjunctival retraction may result in exposure of the implant. You may experience the feeling that something is in your eye or eye discharge/watering
  • Rhegmatogenous retinal detachment: This is a separation of one of the layers (retina) in the back of the eye that senses light. You may experience flashing lights, a change in your vision, or a loss of vision
  • Implant dislocation: Tell your Retina Specialist immediately if you notice that the implant has moved out of place
  • Implant damage: Damage to the implant may disrupt your treatment and refill schedule. If the implant cannot be properly refilled, your Retina Specialist may remove the implant and/or change your treatment
  • Vitreous hemorrhage: This occurs when blood leaks into the gel-like fluid of the eye. This can cause symptoms such as black spots, blurriness, and shadows in your vision
  • Conjunctival bleb: This occurs when a small bump appears in the layer (conjunctiva) that covers the white part of the eye where the implant is located. You may experience a feeling that something is in your eye or eye discharge/watering
  • Temporary decrease in vision after the SUSVIMO procedure

The most common side effects of SUSVIMO:

  • Blood in the white part of the eye
  • Eye pain
  • Redness in the layer that covers the white of the eye
  • Inflammation in the colored part of the eye

These are not all the possible side effects of SUSVIMO. If necessary, SUSVIMO can be removed in an outpatient procedure.

If you experience any side effects, notify your Retina Specialist immediately.

If you miss a scheduled refill, call your Retina Specialist as soon as possible to reschedule. Keeping your schedule is important—it’s the best way to ensure your Retina Specialist can monitor your vision.

When someone finds out they have wet AMD, they may be overwhelmed about their treatment. You can play an important part in helping manage their vision challenges and easing their concerns. The best ways to help are ensuring they adhere to post-operation guidance and keep up with their treatment schedule. In addition, educate yourself about the SUSVIMO procedures and what to do in case of side effects.

See our Downloadable Resources and Caregiver Resources to learn more ways to help.

Get help understanding your insurance coverage and assistance options from Genentech Ophthalmology Access Solutions. Genentech Ophthalmology Access Solutions can help you learn if your health insurance covers SUSVIMO treatment and refer you to appropriate financial assistance options if you are eligible.

Visit Genentech Ophthalmology Solutions

Question mark

Have questions or need assistance?

Just call (833) EYE-GENE/(833) 393-4363 and one of our representatives will be with you soon.

Our representatives are available Monday–Friday, 9 am–8 pm Eastern Time.

For patients with wet AMD previously treated with at least 2 intravitreal injections of a VEGF inhibitor medication.

†In a clinical trial, SUSVIMO patients maintained vision as well as patients on monthly ranibizumab injections at weeks 36 and 40, as measured by the best corrected visual acuity score.

‡In certain cases, you may be given an additional treatment in the SUSVIMO-treated eye if your Retina Specialist decides it is necessary.

See helpful links

Important Safety Information

What is SUSVIMO (ranibizumab injection)?

SUSVIMO is a prescription medicine used to treat adults with neovascular (wet) Age‐related Macular Degeneration (AMD) who have responded to at least two injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor in the gel-like part of the eye (intravitreal). It is not known if SUSVIMO is safe and effective in children.

What is the most important information I should know about SUSVIMO?

SUSVIMO (ranibizumab injection) is delivered into the eye using the SUSVIMO implant. The SUSVIMO implant and the procedures to insert, fill, refill, and remove the eye (ocular) implant can cause serious side effects, including:

  • An eye infection (endophthalmitis). Endophthalmitis is an infection of the eyeball that can cause permanent damage to your eye, including blindness. Call your healthcare provider right away if you have increasing eye pain, vision loss, sensitivity to light, or redness in the white of the eye. Endophthalmitis requires urgent (same-day) medical or surgical treatment
  • A missing layer on top of the white part of the eye (conjunctival erosion). Conjunctival erosion is an area that becomes missing (defect) in the layer (conjunctiva) that covers the white part of the eye, which may result in exposure of the implant. Call your healthcare provider right away if you have a sudden feeling that something is in your eye, eye discharge, or watering of the eye. Conjunctival erosion may require surgical treatment
  • An opening of the layer that covers the white part of the eye (conjunctival retraction). Conjunctival retraction is an opening or gaping in the layer (conjunctiva) that covers the white part of the eye, which may cause the implant to be exposed. Call your healthcare provider right away if you have a sudden feeling that something is in your eye, eye discharge, or watering of the eye. Conjunctival retraction may require surgical treatment

Do not receive SUSVIMO if you:

  • Have an infection in or around your eye
  • Have active swelling around your eye that may include pain and redness
  • Are allergic to ranibizumab or any of the ingredients in SUSVIMO

Talk to your healthcare provider before receiving SUSVIMO if you have any of these conditions.

Before receiving SUSVIMO, tell your healthcare provider about all of your medical conditions, including if you:

  • Are currently taking or have recently taken medicines that lower the chance of blood clots forming in the body, such as warfarin, low or regular doses of aspirin, or nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Are pregnant or plan to become pregnant. It is not known if SUSVIMO will harm your unborn baby. You should use birth control during your treatment with SUSVIMO and for 12 months after your last dose of SUSVIMO 

What are other possible side effects of SUSVIMO?

The SUSVIMO implant and the procedures to insert, fill, refill, and remove the eye (ocular) implant can cause other serious side effects, including: 

  • Tear and separation of layers of the retina (rhegmatogenous retinal detachment). Rhegmatogenous retinal detachment is a tear and separation of one of the layers of the retina in the back of the eye that senses light. Call your healthcare provider or go to the emergency room right away if you see flashing lights, see a curtain or veil covering part of your vision, or have a change in, or a loss of, vision. Rhegmatogenous retinal detachment requires surgical treatment
  • Implant movement (implant dislocation): Tell your healthcare provider right away if you notice that the implant has moved out of place. This movement may require surgical treatment to correct
  • Implant damage: Damage to the implant that prevents continued treatment (refills) with SUSVIMO. If the implant is not able to be properly refilled, your wet AMD may be inadequately treated and your physician may remove the implant and/or change your treatment
  • Bleeding (vitreous hemorrhage): Vitreous hemorrhage is bleeding within the gel-like substance (vitreous) inside of your eye. Call your healthcare provider right away if you have an increase in moving spots or what looks like spider webs in your vision, as you may need an additional eye surgery
  • Bump on top of the white layer of the eye (conjunctival bleb): Conjunctival bleb is a small bulge in the layer (conjunctiva) that covers the white part of the eye where the implant is inserted. This may be due to leakage of fluid from the inside of the eye. Call your healthcare provider right away if you have a sudden feeling that something is in your eye (foreign body sensation), see a bulge over the white part of your eye, have eye discharge, or have watering in the eye. You may need medical or surgical treatment
  • Temporary decrease in vision after the SUSVIMO procedure

The most common side effects of SUSVIMO include:

  • Blood on the white of the eye
  • Eye pain
  • Redness in the white of the eye
  • Sensitivity to light

These are not all the possible side effects of SUSVIMO. 

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555. 

Please see Important Safety Information, including Serious Side Effects, as well as the SUSVIMO full Prescribing Information and Medication Guide.

Back to Top

    • SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.

      SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.

    • Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126:1141-1154.

      Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126:1141-1154.

    • SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.

      SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.

    • Monés J, Gune S, Maia M, et al. Pharmacokinetic profile of the port delivery system with ranibizumab in the phase 3 Archway trial. Presented at 21st EURETINA Congress, September 9-12, 2021.

      Monés J, Gune S, Maia M, et al. Pharmacokinetic profile of the port delivery system with ranibizumab in the phase 3 Archway trial. Presented at 21st EURETINA Congress, September 9-12, 2021.

    • Ranade SV, Wieland MR, Tam T, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Delivery. 2022;29(1):1326-1334.

      Ranade SV, Wieland MR, Tam T, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Delivery. 2022;29(1):1326-1334.

    • Data on file. Genentech, Inc. 2021.

      Data on file. Genentech, Inc. 2021.

    • Data on file. Genentech, Inc. 2021.

      Data on file. Genentech, Inc. 2021.

    • Holekamp NM, Campochiaro PA, Chang MA, et al; Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295-307.

      Holekamp NM, Campochiaro PA, Chang MA, et al; Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295-307.

    • A phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration. ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934

      A phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration. ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934

    • Wykoff CC; Archway Investigators. 2-year outcomes from the phase 3 Archway trial: management of neovascular age-related macular degeneration using the port delivery system with ranibizumab (PDS). Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition, February 11-12, 2022.

      Wykoff CC; Archway Investigators. 2-year outcomes from the phase 3 Archway trial: management of neovascular age-related macular degeneration using the port delivery system with ranibizumab (PDS). Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition, February 11-12, 2022.

    • Data on file. Genentech, Inc. 2021.

      Data on file. Genentech, Inc. 2021.

    • Data on file. Genentech, Inc. 2021.

      Data on file. Genentech, Inc. 2021.

    • Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmology. Published online June 16, 2022.

      Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmology. Published online June 16, 2022.